Skip to main content

Table 5 Summary of the most important published studies on observation management of desmoid tumor patients

From: Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors

Study Patients (n) Abdominal/ Extra-abdominal (n) Primary/Recurrent (n) Median tumor size (cm) Median follow-up (months) Observation alone (n) PD (n, %) SD to PR (n, %) Regression (n, %) Tumor behavior Comparison of PFS between observation and other treatments
Bonvalot et al. [12] 112 46/66 112/0 6 76 11 3 (27%) NR NR NR NR
Fiore et al. [3] 142 48/94 74/68 6 33 83 33 (40%) 47 (57%) 3 (4%) 47% PFS at 60 months No difference in PFS between observation and chemotherapy
Barbier et al. [13] 26 0/26 11/15 NR 22 26 1 (4%) 24 (92%) 1 (4%) Median time to stabilization 14 months NR
Salas et al. [14] 426 120/306 426/0 7 52 27 6 (22%) 16 (59%) 5 (19%) Median delay to progression 19.7 months NR
Briand et al. [15] 73 0/73 31/24 7.5 73 55 5 (9%) 42 (76%) 5 (9%) Median time to stabilization 9 months NR
Huang et al. [16] 214 104/100 153/61 5.5 45 20 4 (20%) 14 (70%) 2 (10%) Median delay to progression 15.3 months NR
Park et al. [17] 47 7/40 47/0 8 36 20 1 (5%) 18 (90%) 1 (5%) 92% PFS at 36 months Superior PFS in observation compared to surgery
Burtenshaw et al. [18] 213 213/0 195/18 6 54 63 4 (6%) 36 (57%) 23 (37%) NR NR
Penel et al. [19] 771 374/397 NR 5.7 32 388 117 (30%) NR NR 58% PFS at 24 months No difference in PFS between observation and surgery
Orbach et al. [20] 154 NR NR NR 21 54 32 (59%) 9 (17%) 4 (7%) NR No difference in PFS between observation, surgery and chemotherapy
Cassidy et al. [21] 160 84/76 NR 4.7 15 37 10 (27%) NR NR NR NR
van Broekhoven et al. [22] 91 25/66 NR NR 16 37 5 (14%) 25 (68%) 2 (5%) NR NR
van Houdt et al. [23] 168 76/92 NR 5.9 41 168 60 (36%) 60 (36%) 45 (27%) NR NR
Turner et al. [24] 103 42/61 NR 6.2 35 50 21 (42%) 29 (58%) 0 38% PFS at 36 months NR
de Bruyns et al. [25] 227 89/138 NR 5.4 77 55 13 (24%) 20 (36%) 22 (40%) 71% PFS at 24 months NR
  1. PD progression disease, SD stable disease, PR partial response, PFS progression-free survival, NR not reported